MGTX
MeiraGTx Holdings plc
NASDAQ · Healthcare · Biotechnology · US
$13.89
−0.57%Year over year
Reported trailing growth
- Revenue
- +948.3%
- EBITDA
- +296.6%
- EBIT
- +216.5%
- EPS
- +137.3%
- Free cash flow
- +104.7%
- Operating cash flow
- +110.6%
Forward estimates
Based on analyst estimates
- Revenue
- -93.4%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +72.3%
- EBITDA
- +26.5%
- EBIT
- +35.5%
- Net income
- +22.7%
- EPS
- +33.0%
- Free cash flow
- +54.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026